演讲题目
以IBD为例:双特异性抗体,交联剂和蛋白质相互作用抑制剂作为新的药物疗法如何使患者受益

Jeffery Cowden

Executive Director of Pharmacology, Pharmalegacy Laboratoires

Jeffery is an experience drug hunter with over 18 years of working experience at international pharmaceutical companies Janssen (JNJ), Eli Lilly and Takeda focusing autoimmunity, IBD, allergy and cancer. He has published on the effects of novel drugs in RA, asthma and atopic dermatitis. His work has contributed to 8 IND filings over his career. He is currently executive directory at Pharmalegacy Laboratories where he collaborates with international and Chinese R&D company to design their pre-clinical strategy for new pharmaceutical agents,